Significant decrease in efficacy against new Sarscov2 variants



4/6/2021, 9:04:43 AM

While new dominant sarscov2 variants of concern taking over the globe, vaccine advocates continue to claim efficacy against dominant sarscov2 variants despite significant 2.2-6-8X decline in neutralizing antibody ability. Thle T cell immunity against now predominant new variants(B1351; P.1 etc) is overstated. The reality is vaccines efficacy drops to 15-33% from 90s%. The study shows very low numbers of predominantly t helpers cd4 providing intercellular signaling and infection memory, but not a real defense while cytotoxic cd8 cells are produced&circulate in extremely low concentration